Intellipharmaceutics International Inc. (IPCIF) Research

Intellipharmaceutics International Inc. operates as a pharmaceutical firm primarily engaged in the research, development, and manufacturing of both novel and generic oral solid dosage medications that feature controlled and targeted release mechanisms. The company's U.S. operations are central to its work. Leveraging its unique and patented Hypermatrix technology, Intellipharmaceutics is dedicated to creating advanced drug delivery systems and cultivating a robust pipeline of product candidates across various therapeutic domains. These include critical areas such as neurological disorders, cardiovascular health, gastrointestinal conditions, diabetes, and pain management. The company's current commercial portfolio includes a variety of extended-release and delayed-release products. These offerings address conditions like hyperactivity disorder (Focalin XR), epilepsy (Keppra XR, Lamictal XR), depression (Effexor XR, Pristiq, Seroquel XR), gastroesophageal reflux disease (Protonix), type 2 diabetes (Glucophage XR), schizophrenia and bipolar disorder (Seroquel XR), heart failure and hypertension (Coreg CR), and chronic angina (Ranexa). Additionally, Intellipharmaceutics is actively progressing several developmental compounds, such as an oxycodone hydrochloride controlled-release capsule (OxyContin) for pain management and a pregabalin extended-release capsule (Regabatin XR) designed for neuropathic pain. The company has established a licensing and commercialization partnership with Par Pharmaceutical Inc. Established in 1998, Intellipharmaceutics International Inc. is based in Toronto, Canada.

Open Intellipharmaceutics International Inc. (IPCIF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.